Searching the Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Despite the success of anti-programmed cell death-1 (anti-PD-1) immunotherapy, many cancer patients remain unresponsive, and reliable predictive biomarkers are lacking. Here, we show that aberrant expression of the pyrimidinergic receptor P2RY6 is frequent in human cancers and causes immune evasion. In mouse syngeneic and human xenograft tumor models, ectopic expression of P2RY6 shapes an immunosuppressive tumor microenvironment (TME) to enhance tumor growth and resistance to immunotherapy, whereas deletion of P2RY6 from tumors with high P2RY6 expression inflames the TME to inhibit tumor growth. As a G protein-coupled receptor, P2RY6 activates Gq/phospholipase C-β signaling and stimulates the synthesis of prostaglandin E2, which is a key mediator of immunosuppression in the TME. In contrast to the essential role of P2RY6 in tumors, global deletion of P2ry6 from mice does not compromise viability. Our study thus nominates P2RY6 as a precision immunotherapy target for patients with high tumor-intrinsic P2RY6 expression.
Pubmed ID: 38996067
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This monoclonal targets CD4
View all literature mentionsThis monoclonal targets CD90/CD90.1
View all literature mentionsThis monoclonal targets PD-L1
View all literature mentionsThis monoclonal targets H-2Kb/H-2Db
View all literature mentionsThis monoclonal targets TCR beta chain
View all literature mentionsThis monoclonal targets COX1 / Cyclooxygenase 1 antibody [EPR5866]
View all literature mentionsThis polyclonal secondary targets IgG
View all literature mentionsThis monoclonal targets CD3epsilon
View all literature mentionsThis monoclonal targets H-2Kb bound to SIINFEKL
View all literature mentionsThis monoclonal targets CD90.2
View all literature mentionsThis monoclonal targets β-actin
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets G protein alpha 13 antibody [EPR5436]
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis recombinant monoclonal targets GNAQ
View all literature mentionsThis recombinant monoclonal targets Cox2
View all literature mentionsThis recombinant monoclonal targets CD8 alpha
View all literature mentionsThis monoclonal targets NK-1.1
View all literature mentionsThis recombinant monoclonal targets PLCB1/3
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis polyclonal targets GNA11
View all literature mentionsMus musculus with name C57BL/6J from IMSR.
View all literature mentionsMus musculus with name BALB/cJGpt from IMSR.
View all literature mentions
Mus musculus with name NOD/ShiLtJGpt-Prkdcem26Cd52Il2rg
Mus musculus with name BALB/cNj-Foxn1nu/Gpt from IMSR.
View all literature mentions